The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2024 | Multi-omic evaluation of immunologic changes in patients with CLL treated with venetoclax
In this video, Matthew Cortese, MD, Roswell Park Comprehensive Cancer Center, Buffalo, NY, shares insights into a multi-omic study that used a combination of transcriptomics, RRBS, advanced flow cytometry, and metabolomics to analyze the effects of venetoclax on the immune system in 13 patients with chronic lymphocytic leukemia (CLL). Results showed significant T-cell repair and immune system recovery in patients treated with venetoclax, which could lead to improved outcomes with CAR T-cell therapy and other immunotherapies. This interview took place at the 66th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
